日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

一种提高莫苏妥珠单抗治疗复发或难治性滤泡性淋巴瘤获益风险比的新型递增剂量方案

Li, Chi-Chung; Bender, Brendan; Wilkins, Justin; Li, Feifei; Turner, David C; Wang, Bei; Deng, Rong; Vadhavkar, Shweta; Li, Zao; Kwan, Antonia; Huang, Huang; Peng, Kun; Penuel, Elicia; Huw, Ling-Yuh; Chanu, Pascal; Li, Chunze; Yin, Shen; Wei, Michael C

Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients

量化伊帕他替尼在癌症患者临床前和临床研究中引起QT间期延长的风险

Poon, Victor; Sutaria, Dhruvitkumar; Prell, Rodney; Halpern, Wendy; Wong, Lisa; Harris, Adam; Wilkins, Justin; Yoshida, Kenta; Sane, Rucha

Interplay between pharmacokinetics and immunogenicity of therapeutic proteins: stepwise development of a bidirectional joint pharmacokinetics-anti-drug antibodies model

治疗性蛋白的药代动力学与免疫原性之间的相互作用:双向联合药代动力学-抗药物抗体模型的逐步构建

van der Walt, Jan-Stefan; Wilkins, Justin; Khandelwal, Akash; Venkatakrishnan, Karthik; Gao, Wei; Milenković-Grišić, Ana-Marija

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

莫苏妥珠单抗在中国复发或难治性滤泡性淋巴瘤患者中的药代动力学和药效学的种族敏感性评估

Li Junyi, Liao Michael Z, Wilkins Justin, Penuel Elicia, Wang Bei, Vadhavkar Shweta, Peng Kun, Cao Junning, Li Zhiming, Zhang Ye, Li Wenjin, Li Donghang, Zhou Mingzhu, Wei Michael C, Kwan Antonia, Zhao Rong, Li Chunze, Li Chi-Chung, Turner David C

Covariate modeling in pharmacometrics: General points for consideration

药物计量学中的协变量建模:需要考虑的一般要点

Sanghavi, Kinjal; Ribbing, Jakob; Rogers, James A; Ahmed, Mariam A; Karlsson, Mats O; Holford, Nick; Chasseloup, Estelle; Ahamadi, Malidi; Kowalski, Kenneth G; Cole, Susan; Kerwash, Essam; Wade, Janet R; Liu, Chao; Wang, Yaning; Trame, Mirjam N; Zhu, Hao; Wilkins, Justin J

Semi-mechanistic population pharmacokinetic/pharmacodynamic modeling of a Plasmodium elongation factor 2 inhibitor cabamiquine for prevention and cure of malaria

疟原虫延伸因子 2 抑制剂卡巴米喹预防和治疗疟疾的半机制群体药代动力学/药效学模型

Courlet, Perrine; Wilkins, Justin J; Oeuvray, Claude; Gao, Wei; Khandelwal, Akash

Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside

疟原虫延伸因子 2 抑制剂 M5717 肝期活性转化:从实验室到临床

Khandelwal, Akash; Arez, Francisca; Alves, Paula M; Badolo, Lassina; Brito, Catarina; Fischli, Christoph; Fontinha, Diana; Oeuvray, Claude; Prudêncio, Miguel; Rottmann, Matthias; Wilkins, Justin; Yalkinoglu, Özkan; Bagchus, Wilhelmina M; Spangenberg, Thomas

Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study

IPATential150 研究中转移性去势抵抗性前列腺癌患者接受 ipatasertib 治疗的暴露-反应关系特征分析

Kotani, Naoki; Wilkins, Justin J; Wade, Janet R; Dang, Steve; Sutaria, Dhruvitkumar S; Yoshida, Kenta; Sundrani, Sameer; Ding, Hao; Garcia, Josep; Hinton, Heather; Sane, Rucha; Chanu, Pascal

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

基于模型的方法用于管理bintrafusp alfa(一种靶向TGF-β和PD-L1的双功能融合蛋白)的出血毒性风险管理

Vugmeyster, Yulia; Grisic, Ana-Marija; Wilkins, Justin J; Loos, Anja H; Hallwachs, Roland; Osada, Motonobu; Venkatakrishnan, Karthik; Khandelwal, Akash

R and nlmixr as a gateway between statistics and pharmacometrics

和 nlmixr 作为统计学和药物计量学之间的桥梁

Fidler, Matthew; Hooijmaijers, Richard; Schoemaker, Rik; Wilkins, Justin J; Xiong, Yuan; Wang, Wenping